Universtity Hospital Basel
Welcome,         Profile    Billing    Logout  
 9 Trials 
15 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Liechti, Matthias E
NCT03781128: Lysergic Acid Diethylamide (LSD) as Treatment for Cluster Headache

Recruiting
2
30
Europe
Lysergic Acid Diethylamide, LSD, Placebo
University Hospital, Basel, Switzerland
Cluster Headache
12/24
12/24
NCT05200936 / 2020-001098-55: Safety and Efficacy of Low Dose MM-120 for ADHD Proof of Concept Trial

Completed
2
53
Europe
MM-120, Placebo
Mind Medicine, Inc., Mind Medicine, Inc.
ADHD, Attention Deficit Disorder
11/23
12/23
OxyTUTION, NCT06036004: Oxytocin Substitution Therapy in Patients With Central Diabetes Insipidus

Recruiting
2
112
Europe
Intranasal OXT, Placebo nasal spray
University Hospital, Basel, Switzerland
Central Diabetes Insipidus (cDI)
10/26
10/26
LPM, NCT04227756: Comparative Acute Effects of LSD, Psilocybin and Mescaline

Completed
1
32
Europe
LSD, Psilocybin, Mescaline, Placebo
University Hospital, Basel, Switzerland
Healthy
09/22
09/22
MDR, NCT04849013: Role of the Serotonin 5-HT2A Receptor in Mescaline-induced Altered States of Consciousness

Completed
1
16
Europe
Placebo, Mescaline 100mg, Mescaline 200mg, Mescaline 400mg, Mescaline 800mg, Mescaline 800mg + Ketanserin 40mg
University Hospital, Basel, Switzerland
Healthy
03/23
03/23
LSD-Bio, NCT04865653: LSD Base and LSD Tartrate Bioequivalence and Bioavailability in Healthy Subjects

Completed
1
20
Europe
Lysergic Acid Diethylamide Base oral drinking solution, LSD, Lysergic Acid Diethylamide Base solid orodispersible film, Lysergic Acid Diethylamide Tartrate oral drinking solution, Lysergic Acid Diethylamide Tartrate intravenous administration, LSD Placebo, Placebo
University Hospital, Basel, Switzerland
Healthy
10/23
10/23
DMT DR, NCT05384678: Acute Dose-dependent Effects of DMT in Healthy Subjects

Completed
1
24
Europe
N,N-Dimethyltryptamine (54 mg), N,N-Dimethyltryptamine (108 mg), N,N-Dimethyltryptamine (162 mg), N,N-Dimethyltryptamine (216 mg), Placebo, N,N-Dimethyltryptamine (108 mg) + dose titration
University Hospital, Basel, Switzerland
Healthy
03/24
03/24
DMT BDR, NCT05695495: Acute Dose-dependent Effects of DMT-bolus Applications in Healthy Subjects (-Study)

Not yet recruiting
1
36
Europe
N,N-Dimethyltryptamine (5mg), N,N-Dimethyltryptamine (10mg), N,N-Dimethyltryptamine (15mg), N,N-Dimethyltryptamine (20mg), N,N-Dimethyltryptamine (25mg), Placebo (saline)
University Hospital, Basel, Switzerland
Healthy
12/24
01/25
MDMA-like, NCT04847206: Effects of Substances in Healthy Subjects

Completed
1
23
Europe
3,4-methylenedioxymethamphetamine, MDMA, 3,4-methylenedioxyamphetamine, MDA, lysine-3,4-methylenedioxymethamphetamine, lysine-MDMA, lysine-3,4-methylenedioxyamphetamine, lysine-MDA, Placebo
University Hospital, Basel, Switzerland
Healthy
06/24
06/24
R-S-MDMA, NCT05277636: Acute Effects of R- and S-MDMA in Healthy Subjects

Completed
1
24
Europe
3,4-methylenedioxymethamphetamine, MDMA, S-3,4-methylenedioxymethamphetamine, S-MDMA, R-3,4-methylenedioxymethamphetamine (125 mg), R-MDMA, R-3,4-methylenedioxymethamphetamine (250 mg), Placebo
University Hospital, Basel, Switzerland
Healthy
01/24
01/24
SERT-LSD, NCT05175430: Effects of SERT Inhibition on the Subjective Response to LSD in Healthy Subjects

Completed
1
24
Europe
Paroxetine, Lysergic Acid Diethylamide, LSD, Placebo
University Hospital, Basel, Switzerland
Healthy
02/24
03/24
2C-B, NCT05523401: Acute Effects of Compared With MDMA and Psilocybin in Healthy Subjects

Recruiting
1
24
Europe
4-bromo-2,5-dimethoxyphenethylamine (10 mg), 2C-B, 4-bromo-2,5-dimethoxyphenethylamine (20 mg), 4-bromo-2,5-dimethoxyphenethylamine (30 mg), 3,4-methylenedioxymethamphetamine, MDMA, Psilocybin, Placebo
University Hospital, Basel, Switzerland
Healthy
10/24
10/24
DPS, NCT06180759: Acute Analgesic Effects of DMT on Experimentally Induced Pain in Healthy Participants

Recruiting
1
18
Europe
Intravenous infusion of DMT, Intravenous infusion of ketamine, Intravenous infusion of placebo
University Hospital, Basel, Switzerland
Healthy
08/25
09/25
PDR, NCT06796361: Role of the Serotonin 2A Receptor in Psilocybin-induced Altered States of Consciousness

Not yet recruiting
1
16
Europe
Ketanserin 40mg plus Psilocybin 40mg, 40mg Psilocybin, 20mg Psilocybin, 10mg Psilocybin, 5mg Psilocybin, Placebo
University Hospital, Basel, Switzerland
Healthy
08/26
08/26
NCT05809271: Acute Effects of 3,4-methylenedioxymethamphetamine (MDMA) With and Without a Booster Dose

Active, not recruiting
1
24
Europe
MDMA 120 mg + MDMA 60 mg, 3,4-Methylenedioxymethamphetamine, MDMA 120 mg + placebo, Placebo
University Hospital, Basel, Switzerland
Healthy
03/25
03/25

Download Options